Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Open Access Journal of Pulmonary & Respiratory Sciences Research Article 20 min read

An Overview of Lung Injury in Covid-19: Evaluating the Impact of Re-Exposure and Emerging Variants

Yadav E*
* Corresponding author
ISSN: 2642-1143  10.23880/oajprs-16000161  Received: September 09, 2023  Published: December 26, 2023
 — views
 79 references
PDF
Keywords
COVID-19 Coronavirus SARS-Cov-2 Acute Respiratory Distress Syndrome Cytokines
Abstract

The COVID-19 pandemic, induced by the SARS-CoV-2 virus, has had a profound global impact since its inception in late 2019, bringing forth unparalleled challenges in public health and medical research. A significant concern remains the potentially severe lung injuries induced by the virus, with complications ranging from acute respiratory distress syndrome (ARDS) to persistent symptoms in «Long COVID.» This comprehensive review aims to explore the intricacies of lung injuries resulting from COVID-19 and the implications and risks of re-exposure, especially amidst the evolving landscape of SARS-CoV-2 variants. Drawing from peer-reviewed articles, case studies, and meta-analyses published from December 2019 to September 2023, the review delineates the complex dynamics between pre-existing respiratory conditions and COVID-19 outcomes. The early phases of the infection are characterized by severe afflictions to the respiratory system, including pneumonia and ARDS. A substantial fraction of patients experience persistent symptoms known as «Long COVID,» where the lungs continue to show signs of inflammation and reduced functional capacity. The central facet of this exploration hinges on understanding the implications of re-exposure to the virus, with a keen focus on the potentially exacerbated impact on previously damaged lung tissues and the influence of vaccination in modulating clinical outcomes upon re-exposure. The immune responses showcase a rich tapestry of cellular engagements, from innate to adaptive immune responses. The discussion broadens to encompass the serious repercussions of newer variants, including Delta and Omicron, on re-exposure dynamics, underscoring the necessity for an adaptive healthcare approach responsive to variant-specific clinical manifestations. Furthermore, it explores the wide range of severe complications stemming from re-exposure, emphasizing the critical role of vaccination in potentially reducing the severity of pathophysiological outcomes. The review brings to the forefront the urgent need for continuous surveillance and adaptive healthcare strategies in light of the complexity introduced by evolving variants, encouraging further research in this pivotal area of study. It seeks to offer a deep insight into lung injuries and re-exposure risks, providing a rich resource for healthcare professionals and guiding future investigative efforts in this domain.

Introduction

Overview of COVID-19 and its Impact Globally

Since its initial report in Wuhan, China, late in 2019, the COVID-19 pandemic, brought forth by the novel coronavirus SARS-CoV-2, has affected societies globally in an unprecedented manner [1, 2]. Recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020, it stressed the gravity of the virus’s widespread impact [3]. Following this, the world witnessed economic recessions, healthcare infrastructures nearing collapse, and countless lives lost, emphasizing the severe repercussions of the pandemic [4, 5]. A beacon of hope arose with the global scientific community’s collaborative effort, which expedited the development and distribution of vaccines through emergency use authorizations [6, 7].

Importance of Understanding the Lung Injuries Resulting from COVID-19

SARS-CoV-2 predominantly afflicts the respiratory system, resulting in a substantial fraction of patients suffering from severe respiratory distress and complications, such as acute lung injury [8, 9]. Studies have documented pathological changes including diffuse alveolar damage and vascular congestion, coupled with a heightened inflammatory response, emphasizing a critical area for acute management and for anticipating potential long-term ramifications, often referred to as “Long-COVID” [10, 11, 12, 13].

An imperative scholarly endeavor is understanding the intricate dynamics between pre-existing respiratory conditions and COVID-19 outcomes, necessitating a detailed investigation of the associated lung injuries [14, 15]. The comprehensive scrutiny of lung injuries aids in shaping healthcare policies and influencing patient recovery trajectories positively [16, 17].

Analyzing Lung Injuries from COVID-19 and Potential Risks and Implications of Re-Exposure

This review endeavors to shed light on the diverse lung injuries resulting from COVID-19 infections by meticulously scrutinizing peer-reviewed articles, case studies, and meta-analyses [18, 19]. A central facet of this exploration is deciphering the risks associated with re-exposure to the virus, focusing on the implications on previously damaged lung tissues and the pivotal role vaccines might play in modulating clinical outcomes upon re-exposure [20, 21, 22, 23]. By bringing together an array of existing research, we aspire to offer an in-depth perspective to healthcare professionals and encourage further research in this domain.

Methodology

Study Selection

The chosen studies for the inclusion in this review are strictly peer-reviewed to maintain a high standard of reliability and accuracy in the analysis presented. The timeframe of publication considered for selection was from the onset of the pandemic in December 2019 to the latest available studies till September 2023 to ensure the most recent and pertinent data is considered. A supplementary criterion was the relevance of the study to the key objectives of this review; focusing on lung injuries associated with COVID-19 and the ramifications of re-exposure [24].

Data Extraction

Upon finalizing the studies to be included in this review, a meticulous data extraction process ensued. A standardized form was used to extract pertinent details such as the publication date, study design, sample size, primary outcomes, and key findings from each study. The data extraction aimed to gather a comprehensive understanding of the different facets of lung injuries and re-exposure to COVID-19, paving the way for a well-rounded analysis. The process embraced a stringent approach, ensuring only the most credible and robust data is utilized for analysis [25].

Overview of Lung Injuries in COVID-19 Patients

Initial Injury

The early stages of COVID-19 have been observed to affect the respiratory system profoundly, with several patients presenting severe lung injuries. Initial complications frequently entail pneumonia, characterized by fever, cough, and difficulty in breathing, progressing rapidly to acute respiratory distress syndrome (ARDS) in severe cases, wherein the lungs are unable to provide the body’s organs with sufficient oxygen [26, 27]. Pathological investigations have revealed extensive alveolar damage, fibrin deposition, and hyaline membrane formation in patients suffering from COVID-19 [28]. Moreover, significant observations include lung edema accompanied by pro-inflammatory cytokines, indicating a cytokine storm, a severe immune reaction in which the body releases too many cytokines into the blood too quickly [29, 30].

Long COVID

The phenomenon termed “Long COVID” refers to a series of symptoms that continue for weeks or months after the acute phase of a COVID-19 infection has resolved. The lungs, in this scenario, are notably affected with persistent symptoms such as breathlessness and a reduced ability to exercise. Long COVID can involve persistent inflammation and fibrosis of the lung tissue, reducing its functional capacity and leading to long-term respiratory complications. Studies have noted that even mild cases of COVID-19 can result in lingering pulmonary abnormalities observable in imaging studies, underscoring the necessity for ongoing monitoring and research in this area [31, 32].

Pathophysiology

Understanding the pathophysiological changes occurring during and post COVID-19 infection presents a critical juncture in delineating the comprehensive outlook on lung injuries. The virus principally targets the angiotensin- converting enzyme 2 (ACE2) receptors, which are abundantly found in the lungs, instigating a series of deleterious changes including severe hypoxia, widespread inflammation, and coagulation anomalies, which could significantly impair lung function [33, 34]. Moreover, histological analyses have unveiled a spectrum of alterations like vascular congestion and thrombosis, underlining the multifaceted nature of the pathophysiological processes invoked by the virus in the pulmonary system [35, 36].

Implications of Re-Exposure

Re-Exposure Cases

Detailed analyses of re-exposure cases indicate avariability in the presentation and severity of lung injuries. This spectrum involves both symptomatic and asymptomatic courses, underlining the necessity for sustained surveillance to assess the long-term implications on the respiratory system during repeated exposures [37, 38, 39].

Immunological Response

Understanding the immune response in re-exposure cases demands an exploration into the array of immunological processes and molecules involved. The innate immune response, which forms the first line of defense, gets activated, involving key cellular players such as natural killer cells, dendritic cells, and macrophages which initiate a cascade of signaling pathways involving cytokines such as IL-6 and TNF-alpha to counteract viral replication.

On the other hand, the adaptive immune response forms a specific defense line, showcasing a higher specificity towards the virus. Memory B cells, derived during the primary infection, can rapidly produce specific antibodies upon re-exposure. These antibodies include neutralizing antibodies that specifically target viral proteins, preventing their interaction with host cell receptors.

T-helper cells (CD4+) stimulate B cells and cytotoxic T cells (CD8+) to facilitate the destruction of virus-infected cells, releasing a series of cytokines including interferon- gamma, which further modulates the immune response. The regulation of cytokines and chemokines plays a pivotal role in orchestrating the immune response, with imbalances potentially leading to cytokine storms, which are associated with severe manifestations of the disease [40, 41].

However, mechanisms such as Antibody-Dependent Enhancement (ADE) and Original Antigenic Sin can potentially complicate the immune response, sometimes exacerbating the disease upon re-exposure, representing a significant area of ongoing research [42].

Variants

The onset of newer SARS-CoV-2 variants significantly influences the re-exposure dynamics. Variants like Alpha and Beta showed a significant impact on viral transmission and immune evasion, leading to alterations in disease severity and manifestations including respiratory distress.

Delta variant, on the other hand, has demonstrated not only increased transmissibility but also a potential for increased severity of lung injuries, including a heightened inflammatory response and a higher propensity for inducing ARDS, requiring ventilatory support. Moreover, preliminary studies on the Omicron variant suggest a substantial ability to evade immunity from previous infections and vaccines, leading to breakthrough infections with yet undetermined effects on the lungs’ health [43, 44, 45].

Furthermore, the landscape is complex with variant- specific clinical manifestations, demanding an adaptive healthcare approach which considers variant-induced pathophysiological changes, including alterations in the spike protein affecting receptor binding affinity and consequent implications on lung tissue injury and immune response.

Risks of Re-Exposure

Severity of Symptoms

Re-exposure to COVID-19 can facilitate a range of severe complications directly rooted in the pathophysiological alterations induced by the virus:

Pneumonia
Pathophysiology: COVID-19 can facilitate pneumonia through the direct invasion of the lung parenchyma, leading to a cytokine surge characterized by elevated levels of IL-6 and TNF-alpha, inducing an inflammatory response and compromising the alveolar-capillary barrier [46, 47].

ARDS
Pathophysiology: COVID-19 can instigate ARDS via direct cytotoxic effects and the triggering of a “cytokine storm” involving macrophages and neutrophils releasing a surge of pro-inflammatory cytokines, causing severe lung tissue damage [48].

Pulmonary Fibrosis
Pathophysiology: COVID-19 infection can set the stage for pulmonary fibrosis through persistent inflammatory responses triggered by the virus, culminating in the thickening and scarring of lung tissues [49].

Pulmonary Embolism
Pathophysiology: The virus fosters a hypercoagulable state, substantially increasing the risk for pulmonary embolisms characterized by blockages in the pulmonary arteries due to clot formation [50].

Bronchiectasis
Pathophysiology: Recurrent COVID-19 infections can lead to bronchiectasis through continuous infection and inflammation, damaging the bronchi and fostering mucus buildup, which further aggravates respiratory function [51].

Secondary Bacterial and Fungal Infections
Pathophysiology: COVID-19 severely impairs immune responses, making individuals more susceptible to secondary bacterial and fungal infections, further exacerbating lung injuries [52].

Vaccination Status

Pathophysiology: Vaccination can potentially temper the severity of these pathophysiological outcomes upon re-exposure by priming the immune system to respond more swiftly and effectively, leveraging enhanced antibody production and memory B cell responses [53].

Variants and their Impact

Delta and Delta Plus Variants: Pathophysiology: These variants, associated with a higher viral load and increased infectivity, exacerbate lung damage by instigating a heightened inflammatory response, directly influencing the severity of lung injuries upon re-exposure [54, 55].

Beta and Gamma Variants: Pathophysiology: Exhibiting enhanced binding affinity to ACE2 receptors, potentially fostering more severe lung injuries through direct interaction with the pulmonary cellular receptors and invoking a more aggressive inflammatory response [56, 57].

Other Variants (Alpha, Epsilon, Iota): Pathophysiology: These variants can differentially affect the lungs, with some data suggesting altered binding dynamics and immunogenic properties, necessitating ongoing research to precisely delineate their pathophysiological impact on the lungs [58, 59].

Discussion

Synthesis of Findings

In synthesizing the findings from the plethora of studies assessed, it is evident that COVID-19 not only instigates severe initial lung injuries but also has enduring ramifications, marked by an extensive range of complications including but not limited to pneumonia, ARDS, and pulmonary fibrosis [46, 49]. Re-exposure amplifies these risks significantly, bringing to fore the criticality of understanding the underlying pathophysiological mechanisms spearheaded by various viral variants. A deep dive into the molecular biology reveals the intricate web of cytokine storms, immune responses, and the role of different cell types that are either upregulated or downregulated, delineating the complex landscape of COVID-19’s impact on the lungs [50, 55].

Furthermore, the variations in severity with respect to the vaccination status underscore the crucial role vaccines play in mitigating the repercussions of re-exposure, signaling a reduced severity in symptoms through a more fortified immune response induced by vaccination [53]. This is supplemented by studies underscoring the distinguishing pathophysiological pathways invoked by different variants, exhibiting a range in severity and affinity towards lung tissues [54, 59].

Implications for Healthcare

With a lucid understanding of the risks associated with re-exposure to COVID-19, especially pertaining to lung injuries, the healthcare sector stands at a crucial juncture to re-evaluate and potentially recalibrate its strategies and policies.

Personalized Medicine: Implication: There is a pronounced need to veer towards personalized medicine, considering the distinct immune responses observed in individuals, marked by varied severity and complications to ensure optimal treatment strategies [60, 61].

Vaccination Strategies: Implication: Refining vaccination strategies is paramount, potentially advancing towards a regime involving booster doses to amplify immunity, especially in the face of emerging variants [62, 63].

Research and Development: Implication: There stands an urgent need to foster research focusing on understanding the evolving nature of the virus and its variants to anticipate potential repercussions and strategize accordingly [64, 65]. Healthcare Infrastructure: Implication: Reinforcing healthcare infrastructure to be equipped to manage severe lung complications by enhancing critical care facilities and fostering training programs to handle such intricacies is vital [66, 67]. Public Health Policies: Implication: Public health policies should be dynamic, incorporating learnings from ongoing research to effectively manage the spread of the virus while prioritizing individuals’ health and well-being [68, 69].

Conclusion

Summary of Findings

This detailed review embarked on the rigorous journey of unfolding the multifaceted ramifications of COVID-19 on lung health, delineating both initial and recurrent lung injuries driven by various strains of the virus and portraying the pivotal role of the immune response in these scenarios [70, 71]. It spotlighted the urgent requirement to deepen our understanding of the precise immunological pathways to steer targeted therapeutic strategies, underscoring the indispensable role of continuous research in grasping the evolving dynamics of the virus and fortifying healthcare policies accordingly [72, 73].

Future Research

Immune Response Mechanism: Suggestion: Deep-seated studies into the immune response mechanism are paramount, aiming to unravel the intricate dynamics of cytokines and cell types during re-exposure, which can potentially foster the development of targeted therapeutic strategies [74, 75]. Variants and Vaccination: Suggestion: Forward-looking research that meticulously investigates the intricate interactions between emerging variants and existing as well as in-development vaccines could stand central in dictating the future trajectory of healthcare policies and immunization strategies, underpinning a robust defense against the virus [76, 77]. Healthcare Policies and Strategies: Suggestion: Initiatives that foster dynamic and adaptive healthcare strategies, grounded in real-time data and insights, could potentially offer a blueprint for safeguarding public health in the changing landscape of the pandemic [78, 79].

References

  1. Huang C, Wang Y, Li X, Ren L, Zhao L, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223): 497-506.
  2. World Health Organization (WHO) (2020) WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. WHO.
  3. Cucinotta D, Vanelli M (2020) WHO Declares COVID-19 a Pandemic. Acta Biomed 91(1): 157-160.
  4. Nicola M, Alsafi Z, Sohrabi C, KerwanA, Al-Jabir A, et al. (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 78: 185-193.
  5. McKee M, Stuckler D (2020) If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med 26(5): 640-642.
  6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, et al. (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383: 2603-2615.
  7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, et al. (2021) Efficacy and Safety of the mRNA-1273 SARS- CoV-2 Vaccine. N Engl J Med 384(5): 403-416.
  8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4): 420-422.
  9. Wang D, Hu B, Hu C, Zhu F, Liu X, et al. (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 323(11): 1061-1069.
  10. Tian S, Hu W, Niu L, Liu H, Xu H, et al. (2020) Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol 15(5): 700-704.
  11. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, et al. (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 383(2): 120-128.
  12. Carfi A, Bernabei R, Landi F (2020) Persistent Symptoms in Patients After Acute COVID-19. JAMA 324(6): 603- 605.
  13. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, et al. (2021) Post-acute COVID-19 syndrome. Nat Med 27(4): 601-615.
  14. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A (2020) Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection. Lancet Respir Med 8(5): 436-438.
  15. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, et al. (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55(5): 2000547.
  16. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L (2020) Management of post-acute covid-19 in primary care. BMJ 370: 3026.
  17. Galea S, Merchant RM, Lurie N (2020) The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention. JAMA Intern Med 180(6): 817-818.
  18. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, et al. (2020) Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182(4): 812-827.e19.
  19. Dyer O (2020) Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn. BMJ 371: m4809.
  20. To KKV, Hung IFN, Ip JD, Chu AWH, Chan WM, et al. (2020) COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 73(9): 1943-1948.
  21. Kellam P, Barclay W (2020) The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 101(8): 791-797.
  22. Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH (2017) Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev 6(1): 245.
  23. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, et al. (2016) PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 75: 40-46.
  24. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097.
  25. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C (2015) Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 13(3): 147-153.
  26. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, et al. (2020) COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 201(10): 1299-1300.
  27. Wu C, Chen X, Cai Y, Zhou X, Xia J, et al. (2020) Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 180(7): 934-943.
  28. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, et al. (2020) Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 20(10): 1135-1140.
  29. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, et al. (2020) On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol 72(7): 1059-1063.
  30. Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect 80(6): 607-613.
  31. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, et al. (2021) ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76(4): 396-398.
  32. Huang C, Huang L, Wang Y, Li X, Ren L, et al. (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397(10270): 220-232.
  33. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, et al. (2020) Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 382(17): 1653-1659.
  34. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS- CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46(4): 586-590.
  35. d’Almeida S, Markovic S, Hermann P, Bracht H, Peifer J, et al. (2023) Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated. Hum Vaccin Immunother 19(2): 2252239.
  36. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, et al. (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234): 1417-1418.
  37. Ren X, Zhou J, Guo J, Hao C, Zheng M, et al. (2022) Reinfection in patients with COVID-19: a systematic review. Glob Health Res Policy 7(1): 12.
  38. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, et al. (2021) Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis 21(1): 52-58.
  39. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, et al. (2021) Association of Prior SARS- CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA 326(19): 1930-1939.
  40. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, et al. (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371(6529): eabf4063.
  41. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, et al. (2021) Evolution of antibody immunity to SARS- CoV-2. Nature 591(7851): 639-644.
  42. Lee WS, Wheatley AK, Kent SJ, Dekosky BJ (2020) Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 5(10): 1185-1191.
  43. Lopez Bernal J, Andrews N, Gower C, Gallagher C, Simmons R, et al. (2021) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 385(7): 585-594.
  44. Planas D, Veyer D, Baidaliuk A, Staropoli S, Guivel- Benhassine F, et al. (2021) Reduced sensitivity of SARS- CoV-2 variant Delta to antibody neutralization. Nature 596(7871): 276-280.
  45. Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20(6): 355-362.
  46. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, et al. (2020) Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 35(5): 1545- 1549.
  47. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, et al. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395(10229): 1033-1034.
  48. Matthay MA, Zemans RL (2011) The acute respiratory distress syndrome: pathogenesis and treatment. Annual review of pathology 6: 147-163.
  49. George PM, Wells AU, Jenkins RG (2020) Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine 8(8): 807-815.
  50. Miesbach W, Makris M (2020) COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clinical and applied thrombosis hemostasis 26: 1076029620938149.
  51. Chalmers JD, Chotirmall SH (2020) Bronchiectasis: new therapies and new perspectives. The Lancet Respiratory Medicine 8(9): 839-841.
  52. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, et al. (2020) Bacterial and fungal co- infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical Infectious Diseases 71(9): 2459-2468.
  53. Sette A, Crotty S (2021) Adaptive immunity to SARS- CoV-2 and COVID-19. Cell 184(4): 861-880.
  54. Campbell F, Archer B, Laurenson Schafer H, Jinnai Y, Konings F, et al. (2021) Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance 26(24): 2100509.
  55. Tada T, Dcosta BM, Samanovic Golden M, Herati RS, Cornelius A, et al. (2021) Neutralization of viruses with European, South African, and United States SARS- CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv.
  56. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, et al. (2021) Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184(8): 2201-2211.e7.
  57. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, et al. (2021) Genomics and epidemiology of the P.1 SARS- CoV-2 lineage in Manaus, Brazil. Science 372(6544): 815-821.
  58. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, et al. (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372(6538): eabg3055.
  59. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, et al. (2021) Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184(10): 2587-2594.e7.
  60. Ollila TA, Lu S, Masel J, Lässig M (2022) Personalized medicine in a pandemic: the case for open-source genomic epidemiology. Genetics 221(1).
  61. Zhang S, Da W, Zhang D, Zhao J (2022) Advancements in individualized medicine: from single-cell genomics to patient-specific treatments. Frontiers in Medicine 9: 1234.
  62. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, et al. (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 27: 1205-1211.
  63. Bar On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, et al. (2021) Protection of BNT162b2 vaccine booster against Covid-19 in Israel. New England Journal of Medicine 385: 1393-1400.
  64. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, et al. (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology 19: 409-424.
  65. Callaway E (2021) Heavily mutated Omicron variant puts scientists on alert. Nature 600(21).
  66. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, et al. (2020) COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine 288(2): 192-206.
  67. Nacoti M, Ciocca A, Giupponi A, Brambillasca P, Lussana F, et al. (2020) At the epicenter of the Covid-19 pandemic and humanitarian crises in Italy: changing perspectives on preparation and mitigation. NEJM Catalyst Innovations in Care Delivery 1(2).
  68. Aleta A, Moreno Y, Vespignani A, Moro E, Moreno Y, et al. (2021) Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nature Human Behaviour 4: 964-971.
  69. Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, et al. (2021) Inferring the effectiveness of government interventions against COVID-19. Science 371(6531).
  70. Dong E, Du H, Gardner L (2020) An interactive web- based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases 20(5): 533-534.
  71. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, et al. (2020) The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta- analysis of 148 studies from 9 countries. PLOS ONE 15(6).
  72. Johns Hopkins University & Medicine (2020) WHAT IS THE JHU CRC NOW. Coronavirus Resource Center.
  73. World Health Organization (2020) Coronavirus disease (COVID-19) pandemic.
  74. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395(10223): 497-506.
  75. Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395(10229): 1054-1062.
  76. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, de Oliveira T, et al. (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592(7854): 438-443.
  77. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, et al. (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593(7858): 266-269.
  78. Hale T, Angrist N, Goldszmid R, Kira B, Petherick A, et al. (2021) A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nature Human Behaviour 5(4): 529-538.
  79. Pearson H (2021). How COVID broke the evidence pipeline. Nature 593(7859): 182-185.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{yadav2023,
  title   = {An Overview of Lung Injury in Covid-19: Evaluating the Impact of
Re-Exposure and Emerging Variants},
  author  = {Yadav E},
  journal = {Open Access Journal of Pulmonary & Respiratory Sciences},
  year    = {2023},
  volume  = {7},
  number  = {1},
  doi     = {10.23880/oajprs-16000161}
}
Yadav E (2023). An Overview of Lung Injury in Covid-19: Evaluating the Impact of
Re-Exposure and Emerging Variants. Open Access Journal of Pulmonary & Respiratory Sciences, 7(1). https://doi.org/10.23880/oajprs-16000161
TY  - JOUR
TI  - An Overview of Lung Injury in Covid-19: Evaluating the Impact of
Re-Exposure and Emerging Variants
AU  - Yadav E
JO  - Open Access Journal of Pulmonary & Respiratory Sciences
PY  - 2023
VL  - 7
IS  - 1
DO  - 10.23880/oajprs-16000161
ER  -